Evidence map›Paper›PMID 22937864›Full record

ArticleGenome medicine2012

A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK.

Joshua D Campbell, John E McDonough, Julie E Zeskind, Tillie L Hackett, Dmitri V Pechkovsky, Corry-Anke Brandsma, Masaru Suzuki, John V Gosselink, Gang Liu, Yuriy O Alekseyev and 10 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed
7.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 129 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Vitronectin regulates lung tissue remodeling and emphysema in chronic obstructive pulmonary disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  12. Lung Transcriptomics Link Emphysema to Barrier Dysfunction and Macrophage Subpopulations.American journal of respiratory and critical care medicine · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 3 countries.

Joshua D CampbellDivision of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA ; Bioinformatics Program, Boston University, 44 Cummington Street, Boston, MA 02215, USA.
John E McDonoughUBC James Hogg Research Centre, Providence Heart + Lung Institute, St. Paul's Hospital and Department of Pathology and Laboratory Medicine, University of British Columbia, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
Julie E ZeskindDivision of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA ; Bioinformatics Program, Boston University, 44 Cummington Street, Boston, MA 02215, USA.
Tillie L HackettUBC James Hogg Research Centre, Providence Heart + Lung Institute, St. Paul's Hospital and Department of Pathology and Laboratory Medicine, University of British Columbia, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
Dmitri V PechkovskyUBC James Hogg Research Centre, Providence Heart + Lung Institute, St. Paul's Hospital and Department of Pathology and Laboratory Medicine, University of British Columbia, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
Corry-Anke BrandsmaDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 Groningen, Netherlands.
Masaru SuzukiUBC James Hogg Research Centre, Providence Heart + Lung Institute, St. Paul's Hospital and Department of Pathology and Laboratory Medicine, University of British Columbia, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
John V GosselinkUBC James Hogg Research Centre, Providence Heart + Lung Institute, St. Paul's Hospital and Department of Pathology and Laboratory Medicine, University of British Columbia, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
Gang LiuDivision of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA.
Yuriy O AlekseyevDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA.
Ji XiaoDivision of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA.
Xiaohui ZhangDivision of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA.
Shizu HayashiUBC James Hogg Research Centre, Providence Heart + Lung Institute, St. Paul's Hospital and Department of Pathology and Laboratory Medicine, University of British Columbia, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
Joel D CooperHospital of the University of Pennsylvania, Division of Thoracic Surgery, 3400 Spruce Street 6 White Building, Philadelphia, PA 19104, USA.
Wim TimensDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 Groningen, Netherlands.
Dirkje S PostmaDepartment of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 Groningen, Netherlands.
Darryl A KnightUBC James Hogg Research Centre, Providence Heart + Lung Institute, St. Paul's Hospital and Department of Pathology and Laboratory Medicine, University of British Columbia, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
Marc E LenburgDivision of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA ; Bioinformatics Program, Boston University, 44 Cummington Street, Boston, MA 02215, USA.
James C HoggUBC James Hogg Research Centre, Providence Heart + Lung Institute, St. Paul's Hospital and Department of Pathology and Laboratory Medicine, University of British Columbia, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
Avrum SpiraDivision of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA ; Bioinformatics Program, Boston University, 44 Cummington Street, Boston, MA 02215, USA.
Boston University · USUniversity of British Columbia · CASt. Paul's Hospital · CAUniversity Medical Center Groningen · NLHospital of the University of Pennsylvania · USUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) is a heterogeneous disease consisting of emphysema, small airway obstruction, and/or chronic bronchitis that results in significant loss of lung function over time.

methodsIn order to gain insights into the molecular pathways underlying progression of emphysema and explore computational strategies for identifying COPD therapeutics, we profiled gene expression in lung tissue samples obtained from regions within the same lung with varying amounts of emphysematous destruction from smokers with COPD (8 regions × 8 lungs = 64 samples). Regional emphysema severity was quantified in each tissue sample using the mean linear intercept (Lm) between alveolar walls from micro-CT scans.

resultsWe identified 127 genes whose expression levels were significantly associated with regional emphysema severity while controlling for gene expression differences between individuals. Genes increasing in expression with increasing emphysematous destruction included those involved in inflammation, such as the B-cell receptor signaling pathway, while genes decreasing in expression were enriched in tissue repair processes, including the transforming growth factor beta (TGFβ) pathway, actin organization, and integrin signaling. We found concordant differential expression of these emphysema severity-associated genes in four cross-sectional studies of COPD. Using the Connectivity Map, we identified GHK as a compound that can reverse the gene-expression signature associated with emphysematous destruction and induce expression patterns consistent with TGFβ pathway activation. Treatment of human fibroblasts with GHK recapitulated TGFβ-induced gene-expression patterns, led to the organization of the actin cytoskeleton, and elevated the expression of integrin β1. Furthermore, addition of GHK or TGFβ restored collagen I contraction and remodeling by fibroblasts derived from COPD lungs compared to fibroblasts from former smokers without COPD.

conclusionsThese results demonstrate that gene-expression changes associated with regional emphysema severity within an individual's lung can provide insights into emphysema pathogenesis and identify novel therapeutic opportunities for this deadly disease. They also suggest the need for additional studies to examine the mechanisms by which TGFβ and GHK each reverse the gene-expression signature of emphysematous destruction and the effects of this reversal on disease progression.

Identifiers

PMID22937864
PMCPMC4064320
OpenAlexW2031896302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.